BDNF as a biomarker for successful treatment of mood disorders: A systematic &amp; quantitative meta-analysis

Polyakova, Maryna; Stuke, Katharina; Schuemberg, Katharina; Mueller, Karsten; Schoenknecht, Peter; Schroeter, Matthias L.

doi:10.1016/j.jad.2014.11.044

Cited by 404 publications

(282 citation statements)

References 62 publications

Supporting

Mentioning

246

Contrasting

Unclassified

Order By: Relevance

“…The statistical power calculations using G-Power for Mann-Whitney tests were based on the previous meta-analyses of BDNF and S100B alterations in major depression (Schroeter et al, 2013;Polyakova et al, 2015). These calculations lead to required sample sizes of n = 36 per group for BDNF and n = 5 per group for S100B.…”

Section: Resultsmentioning

confidence: 99%

“…Thus, fluctuations in serum levels of BDNF and S100B seem to be state markers for major depression. This is supported by powerful meta-analyses including a very high number of subjects (Schroeter et al, 2008;Polyakova et al, 2015). NSE is a marker for neuronal injury.…”

Section: Introductionmentioning

confidence: 91%

“…Minor depression is a widespread phenomenon in late life (Hegerl and Schoenknecht, 2009;Polyakova et al, 2015). According to the fourth edition of the diagnostic statistical manual of mental disorders (DSM-IV) a person suffering from two to four depressive symptoms for at least 2 weeks has a minor depressive episode.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression

et al. 2016

View full text Add to dashboard Cite

Minor depression is diagnosed when a patient suffers from 2 to 4 depressive symptoms for at least 2 weeks. Though minor depression is a widespread phenomenon, its pathophysiology has hardly been studied. To get a first insight into the pathophysiological mechanisms underlying this disorder we assessed serum levels of biomarkers for plasticity, glial and neuronal function: brain-derived neurotrophic factor (BDNF), S100B and neuron specific enolase (NSE). 27 subjects with minor depressive episode and 82 healthy subjects over 60 years of age were selected from the database of the Leipzig population-based study of civilization diseases (LIFE). Serum levels of BDNF, S100B and NSE were compared between groups, and correlated with age, body-mass index (BMI), and degree of white matter hyperintensities (score on Fazekas scale). S100B was significantly increased in males with minor depression in comparison to healthy males, whereas other biomarkers did not differ between groups (p = 0.10-0.66). NSE correlated with Fazekas score in patients with minor depression (r s = 0.436, p = 0.048) and in the whole sample (r s = 0.252, p = 0.019). S100B correlated with BMI (r s = 0.246, p = 0.031) and with age in healthy subjects (r s = 0.345, p = 0.002). Increased S100B in males with minor depression, without alterations in BDNF and NSE, supports the glial hypothesis of depression. Correlation between white matter hyperintensities and NSE underscores the vascular hypothesis of late life depression.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Furthermore, anti-depressant treatment of MDD patients increases serum BDNF levels in responders and remitters significantly more than in non-responders, but insufficient data are available for comparing plasma levels in responders versus non-responders (Polyakova et al 2015). This would be an important comparison, as plasma and serum BDNF levels show at least a 100-fold difference (Rosenfeld et al 1995).…”

Section: Peripheral Biomarkersmentioning

confidence: 99%

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Fabbri

Hosák

Mößner

et al. 2016

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under-or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in anti-depressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-a receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.

show abstract

“…Several studies have adopted the BDNF as a molecular candidate for developing bipolar disorder [6,10]. Recent studies had demonstrated that BDNF levels are lower in patients during active phases than BDNF levels in healthy controls [10][11][12][13][14]. Changes in serum BDNF levels in different phases and in following pharmacological interventions for acute affective phase in patients with bipolar disorders were addressed in several studies, but the results are still inconclusive [8,13,[15][16][17].…”

Section: Discussionmentioning

confidence: 99%

Associations between Serum Brain-Derived Neurotrophic Factors and Bipolar Disorder

Wu¹,

Chiou²,

Huang³

2017

Neuropsychiatry

View full text Add to dashboard Cite

show abstract

BDNF as a biomarker for successful treatment of mood disorders: A systematic & quantitative meta-analysis

Cited by 404 publications

References 62 publications

First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression

First Evidence For Glial Pathology In Late Life Minor Depression: s100b Is Increased In Males With Minor Depression

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Associations between Serum Brain-Derived Neurotrophic Factors and Bipolar Disorder

Contact Info

Product

Resources

About